Novartis Aktie
WKN: 904278 / ISIN: CH0012005267
26.06.2007 20:15:00
|
Jacqualyn Fouse to Leave Alcon for New Position
Alcon, Inc. (NYSE:ACL) announced today that effective July 20, 2007,
Jacqualyn Fouse, Alcon’s senior vice
president, chief financial officer and corporate strategy will leave the
company to become chief financial officer of Bunge, Ltd. Fouse joined
Alcon as senior vice president and chief financial officer in July of
2002. The company expects to name a new CFO within the next several
weeks.
"I thank Jackie for her many contributions
while at Alcon and we wish her the best in her new position,"
said Cary Rayment, Alcon’s chairman, president
and chief executive officer.
About Alcon
Alcon, Inc. is the world’s leading eye care
company, with sales of approximately $4.9 billion in 2006. Alcon, which
has been dedicated to the ophthalmic industry for 60 years, researches,
develops, manufactures and markets pharmaceuticals, surgical equipment
and devices, contact lens care solutions and other vision care products
that treat diseases, disorders and other conditions of the eye. Alcon’s
majority shareholder is Nestlé, S.A., the world’s
largest food company.
Caution Concerning Forward-Looking Statements. This press
release may contain forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995. Any
forward-looking statements reflect the views of our management as of the
date of this press release with respect to future events and are based
on assumptions and subject to risks and uncertainties. Given these
uncertainties, you should not place undue reliance on these
forward-looking statements. Except to the extent required under the
federal securities laws and the rules and regulations promulgated by the
Securities and Exchange Commission, we undertake no obligation to
publicly update or revise any of these forward-looking statements,
whether to reflect new information or future events or circumstances or
otherwise.

Wenn Sie mehr über das Thema Aktien erfahren wollen, finden Sie in unserem Ratgeber viele interessante Artikel dazu!
Jetzt informieren!
JETZT DEVISEN-CFDS MIT BIS ZU HEBEL 30 HANDELN
Handeln Sie Devisen-CFDs mit kleinen Spreads. Mit nur 100 € können Sie mit der Wirkung von 3.000 Euro Kapital handeln.
82% der Kleinanlegerkonten verlieren Geld beim CFD-Handel mit diesem Anbieter. Sie sollten überlegen, ob Sie es sich leisten können, das hohe Risiko einzugehen, Ihr Geld zu verlieren.
Nachrichten zu Novartis AGmehr Nachrichten
28.03.25 |
Press Release: FDA approves Novartis radioligand -2- (Dow Jones) | |
28.03.25 |
Press Release: FDA approves Novartis radioligand therapy Pluvicto(R) for earlier use before chemotherapy in PSMA-positive metastatic castration-resistant pro... (Dow Jones) | |
28.03.25 |
Handel in Zürich: SMI zum Start in der Gewinnzone (finanzen.at) | |
27.03.25 |
Schwacher Handel: SLI präsentiert sich letztendlich schwächer (finanzen.at) | |
27.03.25 |
Handel in Europa: STOXX 50 verbucht zum Handelsende Abschläge (finanzen.at) | |
27.03.25 |
Börse Zürich in Rot: SMI beendet den Donnerstagshandel im Minus (finanzen.at) | |
27.03.25 |
Handel in Europa: STOXX 50 gibt nach (finanzen.at) | |
27.03.25 |
Börse Zürich: SLI notiert im Minus (finanzen.at) |
Analysen zu Novartis AGmehr Analysen
06.03.25 | Novartis Buy | Deutsche Bank AG | |
25.02.25 | Novartis Neutral | JP Morgan Chase & Co. | |
20.02.25 | Novartis Outperform | Bernstein Research | |
18.02.25 | Novartis Buy | Deutsche Bank AG | |
13.02.25 | Novartis Neutral | UBS AG |
Aktien in diesem Artikel
Novartis AG | 80,10 | -0,27% |
|
Indizes in diesem Artikel
NYSE US 100 | 16 867,55 | -0,11% |